Catalyst Pharmaceuticals, Inc. (CPRX)
Jul 15, 2026 - CPRX was delisted (reason: acquired by Angelini Pharma)
31.49
0.00 (0.00%)
Inactive · Last trade price on Jul 15, 2026
Catalyst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 596.96 | 588.99 | 491.73 | 398.2 | 214.2 | 140.83 | |
Revenue Growth | 11.65% | 19.78% | 23.49% | 85.90% | 52.10% | 18.27% |
Cost of Revenue | 95.3 | 99.96 | 81.49 | 145.12 | 54.18 | 38.82 |
Gross Profit | 501.66 | 489.03 | 410.24 | 253.09 | 160.02 | 102.01 |
Selling, General & Admin | 196.16 | 193.75 | 177.74 | 133.71 | 57.09 | 49.63 |
Amortization of Goodwill & Intangibles | 37.86 | 37.5 | 37.38 | 32.57 | 1.1 | - |
Operating Expenses | 234.02 | 231.25 | 215.12 | 166.28 | 58.18 | 49.63 |
Operating Income | 267.64 | 257.78 | 195.12 | 86.81 | 101.84 | 52.39 |
Interest & Investment Income | 25.74 | 24.77 | 16.06 | - | - | 0.28 |
Other Non Operating Income (Expenses) | - | - | - | 4.68 | 2.88 | - |
EBT Excluding Unusual Items | 293.38 | 282.54 | 211.19 | 91.49 | 104.72 | 52.67 |
Gain (Loss) on Sale of Investments | 3.08 | 0.97 | 5.08 | 3.02 | - | - |
Pretax Income | 296.46 | 283.52 | 216.26 | 94.51 | 104.72 | 52.67 |
Income Tax Expense | 75.14 | 69.19 | 52.37 | 23.1 | 21.64 | 13.19 |
Net Income | 221.32 | 214.33 | 163.89 | 71.41 | 83.08 | 39.48 |
Net Income to Common | 221.32 | 214.33 | 163.89 | 71.41 | 83.08 | 39.48 |
Net Income Growth | 12.15% | 30.78% | 129.50% | -14.05% | 110.42% | -47.34% |
Shares Outstanding (Basic) | 122 | 122 | 118 | 106 | 103 | 103 |
Shares Outstanding (Diluted) | 127 | 127 | 125 | 114 | 111 | 108 |
Shares Change | 1.12% | 1.85% | 9.84% | 2.14% | 3.32% | 1.46% |
EPS (Basic) | 1.81 | 1.75 | 1.38 | 0.67 | 0.80 | 0.38 |
EPS (Diluted) | 1.73 | 1.68 | 1.31 | 0.63 | 0.75 | 0.37 |
EPS Growth | 10.29% | 28.24% | 107.94% | -16.00% | 102.70% | -47.89% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 208.13 | 208.61 | 239.25 | -54.92 | 106.02 | 59.35 |
Free Cash Flow Per Share | 1.64 | 1.64 | 1.92 | -0.48 | 0.95 | 0.55 |
Gross Margin | 84.04% | 83.03% | 83.43% | 63.56% | 74.70% | 72.44% |
Operating Margin | 44.83% | 43.77% | 39.68% | 21.80% | 47.54% | 37.20% |
Profit Margin | 37.08% | 36.39% | 33.33% | 17.93% | 38.78% | 28.04% |
Free Cash Flow Margin | 34.87% | 35.42% | 48.66% | -13.79% | 49.49% | 42.14% |
EBITDA | 305.83 | 295.65 | 232.9 | 119.69 | 103.08 | 52.58 |
EBITDA Margin | 51.23% | 50.20% | 47.36% | 30.06% | 48.12% | 37.33% |
D&A For EBITDA | 38.19 | 37.87 | 37.77 | 32.88 | 1.24 | 0.19 |
EBIT | 267.64 | 257.78 | 195.12 | 86.81 | 101.84 | 52.39 |
EBIT Margin | 44.83% | 43.77% | 39.68% | 21.80% | 47.54% | 37.20% |
Effective Tax Rate | 25.34% | 24.40% | 24.22% | 24.44% | 20.66% | 25.04% |
Revenue as Reported | 596.96 | 588.99 | 491.73 | 398.2 | 214.2 | 140.83 |
Advertising Expenses | - | 13 | 10 | 9.1 | 3.3 | 2.9 |